| Literature DB >> 28671070 |
A Bonomi1, E Ghezzi2, L Pascucci3, M Aralla2, V Ceserani4, L Pettinari2, V Coccè1, A Guercio5, G Alessandri4, E Parati4, A T Brini6, O Zeira2, A Pessina7.
Abstract
This study investigated whether canine mesenchymal stromal cells (cMSCs) are able to take up and release paclitaxel (PTX) in active form, and therefore whether they have potential as a tool for therapeutic delivery of this drug. cMSCs from bone marrow and adipose tissue were isolated, expanded and characterised phenotypically. cMSCs were loaded with PTX (cMSCs-PTX) and their capacity for release of PTX was determined by their effect on proliferation of cancer cells. cMSCs-PTX derived from bone marrow and adipose tissue were able to take up and then release active PTX. cMSCs-PTC inhibited proliferation of the canine glioma cell line J3T, and the human glioblastoma cell lines T98G and U87MG. The potential of canine cMSCs-PTX for treatment of canine gliomas should be investigated further.Entities:
Keywords: Canine; Drug delivery; Glioma; Mesenchymal stromal cells; Paclitaxel
Mesh：
Substances：
Year: 2017 PMID： 28671070 DOI： 10.1016/j.tvjl.2017.05.005
Source DB: PubMed Journal: Vet J ISSN： 1090-0233 Impact factor: 2.688